30
Participants
Start Date
March 4, 2022
Primary Completion Date
June 3, 2023
Study Completion Date
September 20, 2023
ATB1651, 2 mg/mL
The participants will apply daily doses of ATB1651, 2 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
ATB1651, 5 mg/mL
The participants will apply daily doses of ATB1651, 5 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
ATB1651, 10 mg/mL
The participants will apply daily doses of ATB1651, 10 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
ATB1651, 20 mg/mL
The participants will apply daily doses of ATB1651, 20 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
ATB1651, 30 mg/mL
The participants will apply daily doses of ATB1651, 30 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
Placebo
The participants will apply placebo to all 10 toenails including at least 1 affected great toenail for 28 days
New Zealand Clinical Research Christchurch, Christchurch
Novotech (Australia) Pty Limited
INDUSTRY
AmtixBio Co., Ltd.
INDUSTRY